1 / 8

Colorectal Cancer – Current Status

Colorectal Cancer – Current Status. Professor Paul Horgan Head of Academic Surgery University of Glasgow. Magnitude of the Problem. Second most common cause of cancer death 900,000 new cases worldwide in 2007 20-fold difference Western countries and India 52,180 deaths in the US in 2007.

lew
Download Presentation

Colorectal Cancer – Current Status

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Colorectal Cancer – Current Status Professor Paul Horgan Head of Academic Surgery University of Glasgow

  2. Magnitude of the Problem • Second most common cause of cancer death • 900,000 new cases worldwide in 2007 • 20-fold difference Western countries and India • 52,180 deaths in the US in 2007

  3. Surgery • Best for cure • Optimised/standardised technique and care • Aggressive treatment of stage 4 disease • Adjuvant chemotherapy for stage 3 disease • Personalisation of chemotherapy

  4. Node-negative Disease • Treated with surgery alone • >75% 5 yr survival Stage 2 • >90% Stage 1 • 25-33% recurrent or metastatic disease • How do we improve these poor results?

  5. Adjuvant Chemotherapy • Direct evidence of benefit Stage 3 • 10% increased survival • No direct evidence for stage 2 • 2 – 3%

  6. Negatives • 6-8 months chemotherapy – QUALY • Cost • Mortality 1-4% • Aborted treatment • Morbidity

  7. Sub-populations • Poor prognosis • Perforation, T4, Obstruction, Poor differentiation, Lympho-vascular invasion, margin involvement. • Low lymph node harvest • K-Ras • MSI – H and 5FU resistance • Does this imply use of adjuvant chemo?

  8. Opportunities • Screening and stage • Primary prevention – block, retard or abort • Secondary prevention – risk assessment, screening and early detection • Tertiary prevention – reduce recurrence

More Related